Ebastine CAS 90729-43-4
Introduction：Basic information about Ebastine CAS 90729-43-4, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Ebastine Basic informationDescription References
| Product Name: | Ebastine |
| Synonyms: | 4'-(1,1-Dimethylethyl)-γ-[4-(diphenylmethoxy)piperidin-1-yl]butyrophenone;4'-tert-Butyl-γ-[4-(diphenylmethoxy)piperidino]butyrophenone;Ebastel-OD;LAS-90;IMp. A (EP): DiphenylMethanol (Benzhydrol);Ebastine Impurity;1-butanone,1-(4-(1,1-dimethylethyl)phenyl)-4-(4-(diphenylmethoxy)-1-piperidiny;4’-tert-butyl-4-(4-(diphenylmethoxy)piperidino)butyrophenone |
| CAS: | 90729-43-4 |
| MF: | C32H39NO2 |
| MW: | 469.66 |
| EINECS: | 635-609-6 |
| Product Categories: | Inhibitors;Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;90729-43-4 |
| Mol File: | 90729-43-4.mol |
Ebastine Chemical Properties
| Melting point | 80-82°C |
| Boiling point | 596.3±50.0 °C(Predicted) |
| density | 1.09±0.1 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | Slightly soluble in chloroform, methanol. |
| form | solid |
| pka | 8.19±0.10(Predicted) |
| color | white |
| Merck | 14,3484 |
| InChIKey | MJJALKDDGIKVBE-UHFFFAOYSA-N |
| SMILES | C(C1=CC=C(C(C)(C)C)C=C1)(=O)CCCN1CCC(OC(C2=CC=CC=C2)C2=CC=CC=C2)CC1 |
| CAS DataBase Reference | 90729-43-4(CAS DataBase Reference) |
Safety Information
| WGK Germany | 3 |
| RTECS | EL8140000 |
| HS Code | 2933.39.9200 |
| Storage Class | 11 - Combustible Solids |
| Description | Ebastine belongs to an effective second generation histamine H1 receptor antagonist. One important property of it is that it doesn’t penetrate the blood brain barrier. Therefore, it is capable of blocking the H1 receptor in peripheral tissue without having some specific side effects such as sedation and drowsiness. Ebastine is mainly applied for the treatment of allergic rhinitis, pruritus as well as acting as an alternative drug in Decongestant. Upon entering into the human body, it can subject to the action of hepatic cytochrome P450 3A4 to be converted to an active carboxylic acid metabolite, carebastine. The later one is the major active form in vivo. Under certain range, it can inhibit T cell proliferation and the production of Th2-type pro-inflammatory cytokines through macrophages. Ebastine generally has a high safety property without causing cognitive/psychomotor impairment and sedation, like placebo. However, it can cause side effects such as inflammation of the air-cavities around nose, sore throat, indigestion, nausea, headache, and abdominal pain. |
| References | https://pubchem.ncbi.nlm.nih.gov/compound/3191#section=Top http://www.tabletwise.com/medicine/ebastine/side-effects http://www.druginfosys.com/drug.aspx?drugcode=897&type=1 |
| Description | Ebastine is a new once-daily histamine Hl-receptor antagonist with no sedativeeffects or autonomic impairment at therapeutic doses. It is reported to be effectivein the treatment of hay fever, perennial rhinitis, and uticaria. Ebastine'santihistamine activity is attributed to its carboxylic acid metabolite carebastine. |
| Chemical Properties | White to Off-White Powder |
| Originator | Almirall (Spain) |
| Uses | Ebastine is a second-generation H1 receptor antagonist that is indicated mainly for allergic rhinitis and chronic idiopathic urticaria. It is available in 10 and 20 mg tablets and as fast-dissolving tablets, as well as in pediatric syrup. It has a recommended flexible daily dose of 10 or 20 mg, depending on disease severity. |
| Uses | A nonsedating type histamine H1-receptor antagonist. Antihistaminic |
| Definition | ChEBI: Ebastine is an organic molecular entity. |
| Manufacturing Process | (a) A mixture of 4-hydroxypiperidine (40.4 g; 0.4 moles), p-tert-butyl-ω-chlorobutyrophenone (105 g, 0.44 moles), sodium bicarbonate (67.2 g; 0.8moles) and a crystal of potassium iodide in methyl isobutyl ketone (1 liter)was boiled under reflux for 24 hours. After cooling, the reaction mixture waswashed with water, dried (Na2SO4) and the solvent removed in vacuum. Theresidue was salified with the stoichiometric amount of fumaric acid in amixture of acetone and ethanol to give 1-[3-(4-tert-butylbenzoyl)propyl]-4-hydroxypiperidine fumarate (148 g), melting point 163-165°C. This compoundwas converted into the free base, and 1-[3-(4-tert-butylbenzoyl)propyl]-4-hydroxypiperidine was obtained and recrystallized from a mixture of diethylether and petroleum ether (boiling point 50-70°C). 102 g were obtained (yield84%), melting point 63-65°C. (b) A mixture of 1-[3-(tert-butylbenzoyl)propyl]-4-hydroxypiperidine (60.68 g;0.2 moles) and sodium carbonate (42.4 g; 0.4 moles) in methyl isobutylketone (500 ml) was heated to the boiling point and a solution ofdiphenylmethyl bromide (49.42 g; 0.2 moles) in methyl isobutyl ketone (75ml) was slowly added in 1.5 hours. The resulting mixture was boiled underreflux for another 12 hours, and then another solution of diphenylmethylbromide (24.71 g; 0.1 moles) in methyl isobutyl ketone (50 ml) was addedand the mixture boiled under reflux again for 12 hours. Another solution ofdiphenylmethyl bromide in the same quantity was added and after refluxingfor 12 additional hours the reaction mixture was cooled, washed with water,dried (Na2SO4) and the solvent removed in vacuum. The residual oil was treated with the stoichiometric amount of fumaric acid inethanol and 4-diphenylmethoxy-1-[3-(4-tert-butylbenzoyl)propyl]piperidinefumarate crystallized. After recrystallisation from ethanol the pure compoundwas obtained (88 g; yield 75%), melting point 197-198°C. |
| Brand name | Kestine (Rhone-Poulenc Rorer);Ebastel. |
| Therapeutic Function | Antihistaminic, Antiallergic, Calcium entry blocker |
| General Description | Ebastine is metabolised by cytochrome P450 3A (CYP3A4) to carebastine. It is used to treat allergic rhinitis and chronic idiopathic urticaria. |
| Biochem/physiol Actions | Ebastine is a non-sedating histamine H1 receptor antagonist, which inhibits allergen-induced bronchospasm in conscious guinea pigs. Unlike other compounds in this category, ebastine does not prolong the QT interval at up to five times the recommended therapeutic dose. |
| References | [1] Patent: WO2011/121099, 2011, A2. Location in patent: Page/Page column 39-40 [2] Patent: EP2371817, 2011, A1. Location in patent: Page/Page column 27 |
Ebastine Preparation Products And Raw materials
| Raw materials | 4-Hydroxypiperidine-->Bromodiphenylmethane-->Sodium bicarbonate-->Potassium iodide-->4-(diphenylmethoxy)piperidinium chloride-->4-(DIPHENYLMETHOXY)PIPERIDINE-->4'-tert-Butyl-4-chlorobutyrophenone-->Piperidine, 4-(diphenylmethoxy)-, 4-methylbenzenesulfonate (1:1)-->Potassium carbonate-->4-Methyl-2-pentanone |
| Preparation Products | 1-[4-(1,1-DiMethylethyl)phenyl]-4-[4-(diphenylMethoxy)-1-oxido-1-piperidinyl]-1-butanone |
